HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
Zomedica Pharmaceuticals Corp. (ZOM)
0.1704  -0.0016  (-0.93%) 07-07 15:25
Open: 0.173 High: 0.1785
Pre.close: 0.172 Low: 0.166
Volume: 60,735,905 Ave vol: 56,674,774
52w High: 0.499 52w Low: 0.11
MA(50): 0.199 MA(200): 0.216
EPS: -0.095 P/E Ratio: 0
Company profile
Exchange: AMEX
Sector: Healthcare
Industry: Drug ManufacturersSpecialty & Generic
Website: http://www.zomedica.com
Market Cap (M): 62
Shares Out (M): 361
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc.
Technical analysis
Overall: Underperform
MA: Bearish MACD: Bearish
KDJ: Bearish RSI: Bearish
Target 1: 0.27 Target 2: 0.32
Resist 1: 0.23 Resist 2: 0.28
Support 1: 0.16 Support 2: 0.13
Company key metrics
Revenue per Share: 0
Net Income per Share: -0.1861
Cash per Share: 0.0048
Book Value per Share: 0.0197
Price to Sales: 0
Price to Book Value: 12.1747
Earnings Yield: -0.7755
Dividend Yield: 0
Debt to Equity: 0.9962
Debt to Assets: 0.4991
Financial analysis
Price to Book Value: Underperform
Return on Assets: Outperform
Return on Equity: Underperform
Discounted cash flow: Outperform
Price to Earnings: Outperform
Debt to Equity: Underperform
Stock Charts
Headline news
Wed, 01 Jul 2020
Zomedica Pharmaceuticals Corp. Announces $30 Million Public Offering - GlobeNewswire

Wed, 01 Jul 2020
Zomedica Pharmaceuticals Corp. Announces Proposed Public Offering - GlobeNewswire

Tue, 07 Jul 2020
Here is why Zomedica Pharmaceuticals Corp. (ZOM) stock volatility recorded over the last month was 13.31% - The InvestChronicle

Tue, 30 Jun 2020
Is Zomedica Pharmaceuticals Corp (ZOM) Stock a Good Buy on Tuesday? - InvestorsObserver

Thu, 25 Jun 2020
PCG Research Announces Publication of Update Report Covering Zomedica Pharmaceuticals Corp. - Yahoo Finance

Mon, 06 Jul 2020
Zomedica Pharmaceuticals Corp. (AMEX:ZOM) is Holding Steady - The Oracle Dispatch

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.